Chemotherapy Induced Peripheral Neuropathy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Wex Pharma, Esteve, Algo Therapeutix

Posted on
by

Chemotherapy Induced Peripheral Neuropathy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Wex Pharma, Esteve, Algo Therapeutix
“Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology.

DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology as well as the Chemotherapy Induced Peripheral Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Chemotherapy Induced Peripheral Neuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Peripheral Neuropathy Market Forecast

 

Some of the key facts of the Chemotherapy Induced Peripheral Neuropathy Market Report: 

  • The Chemotherapy Induced Peripheral Neuropathy market size was valued approximately USD 1500 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The overall newly reported cases of CIPN in the 7MM nations reached approximately 1,619,000 in 2022. It is projected to show an increase at a compound annual growth rate (CAGR) of 1.3% throughout the study duration spanning from 2019 to 2032.
  • In 2022, the new cases of CIPN specifically linked to breast cancer accounted for roughly 14% or approximately 92,000 cases of the total CIPN cases reported in the US, encompassing lung, colorectal, pancreatic, and multiple myeloma cancers.
  • In 2022, within European countries, Germany reported the highest number of new cases of CIPN, totaling approximately 175,000 cases, followed by France with an incident population of around 131,500 cases. In contrast, Spain had the lowest number of new CIPN cases, estimated at approximately 80,000 in 2022.
  • Based on research findings, multiple medications are commonly prescribed to manage CIPN. The survey highlighted that the most commonly administered drugs include opioid analgesics, serotonin/norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), alpha-2-delta antagonists, and topical analgesics.
  • Key Chemotherapy Induced Peripheral Neuropathy Companies: Wex Pharmaceuticals, Esteve, Algo Therapeutix, WinSanTor, Inc, Hoffmann-La Roche, Neo Therapeutics, NEMA Research, Inc., Boryung Pharmaceutical, and others
  • Key Chemotherapy Induced Peripheral Neuropathy Therapies: HALNEURON, E-52862 (MR309), ATX01, WST-057 Active, Olesoxime (TRO19622), Tetrodotoxin, leteprinim potassium (Neotrofin), Cesamet™ (nabilone), sodium selenite pentahydrate, and others
  • The Chemotherapy Induced Peripheral Neuropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy Induced Peripheral Neuropathy pipeline products will significantly revolutionize the Chemotherapy Induced Peripheral Neuropathy market dynamics.

 

Chemotherapy Induced Peripheral Neuropathy Overview

Chemotherapy-Induced Peripheral Neuropathy (CIPN) refers to damage or dysfunction in the peripheral nerves caused by certain chemotherapy drugs used to treat cancer. Peripheral nerves are responsible for transmitting signals between the brain, spinal cord, and the rest of the body.

 

Get a Free sample for the Chemotherapy Induced Peripheral Neuropathy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/cipn-market

 

Chemotherapy Induced Peripheral Neuropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chemotherapy Induced Peripheral Neuropathy Epidemiology Segmentation:

The Chemotherapy Induced Peripheral Neuropathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chemotherapy Induced Peripheral Neuropathy
  • Prevalent Cases of Chemotherapy Induced Peripheral Neuropathy by severity
  • Gender-specific Prevalence of Chemotherapy Induced Peripheral Neuropathy
  • Diagnosed Cases of Episodic and Chronic Chemotherapy Induced Peripheral Neuropathy

 

Download the report to understand which factors are driving Chemotherapy Induced Peripheral Neuropathy epidemiology trends @ Chemotherapy Induced Peripheral Neuropathy Epidemiology Forecast

 

Chemotherapy Induced Peripheral Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Peripheral Neuropathy market or expected to get launched during the study period. The analysis covers Chemotherapy Induced Peripheral Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chemotherapy Induced Peripheral Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Chemotherapy Induced Peripheral Neuropathy Therapies and Key Companies

  • HALNEURON: Wex Pharmaceuticals
  • E-52862 (MR309): Esteve
  • ATX01: AlgoTherapeutix
  • WST-057 Active: WinSanTor, Inc
  • Olesoxime (TRO19622): Hoffmann-La Roche
  • Tetrodotoxin: Wex Pharmaceuticals Inc.
  • leteprinim potassium (Neotrofin): NeoTherapeutics
  • Cesamet™ (nabilone): NEMA Research, Inc.
  • sodium selenite pentahydrate: Boryung Pharmaceutical

 

Discover more about therapies set to grab major Chemotherapy Induced Peripheral Neuropathy market share @ Chemotherapy Induced Peripheral Neuropathy Treatment Landscape

 

Chemotherapy Induced Peripheral Neuropathy Market Strengths

  • Certain initiatives have been taken by the private and government organization to raise awareness about the disease.
  • There has been an increase in pharmaceutical companies’ investment for the research and development of the drugs
  • Standardized assessment protocols and objective outcomes measures of CIPN applicable to patients of different ages are critical to enabling the development of novel treatments

 

Chemotherapy Induced Peripheral Neuropathy Market Opportunities

  • Several pharmaceutical key players have taken the initiative to meet the unmet needs of the CIPN market’s present situation.
  • The market also demands a proper diagnostic tools with well-defined markers
  • Increased public awareness creates a lucrative opportunity for innovation of therapeutics to drive the CIPN market.

 

Scope of the Chemotherapy Induced Peripheral Neuropathy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Chemotherapy Induced Peripheral Neuropathy Companies: Wex Pharmaceuticals, Esteve, Algo Therapeutix, WinSanTor, Inc, Hoffmann-La Roche, Neo Therapeutics, NEMA Research, Inc., Boryung Pharmaceutical, and others
  • Key Chemotherapy Induced Peripheral Neuropathy Therapies: HALNEURON, E-52862 (MR309), ATX01, WST-057 Active, Olesoxime (TRO19622), Tetrodotoxin, leteprinim potassium (Neotrofin), Cesamet™ (nabilone), sodium selenite pentahydrate, and others
  • Chemotherapy Induced Peripheral Neuropathy Therapeutic Assessment: Chemotherapy Induced Peripheral Neuropathy current marketed and Chemotherapy Induced Peripheral Neuropathy emerging therapies
  • Chemotherapy Induced Peripheral Neuropathy Market Dynamics: Chemotherapy Induced Peripheral Neuropathy market drivers and Chemotherapy Induced Peripheral Neuropathy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Chemotherapy Induced Peripheral Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy Induced Peripheral Neuropathy Market Access and Reimbursement 

 

To know more about Chemotherapy Induced Peripheral Neuropathy companies working in the treatment market, visit @ Chemotherapy Induced Peripheral Neuropathy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Chemotherapy Induced Peripheral Neuropathy Market Report Introduction

2. Executive Summary for Chemotherapy Induced Peripheral Neuropathy

3. SWOT analysis of Chemotherapy Induced Peripheral Neuropathy

4. Chemotherapy Induced Peripheral Neuropathy Patient Share (%) Overview at a Glance

5. Chemotherapy Induced Peripheral Neuropathy Market Overview at a Glance

6. Chemotherapy Induced Peripheral Neuropathy Disease Background and Overview

7. Chemotherapy Induced Peripheral Neuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Chemotherapy Induced Peripheral Neuropathy 

9. Chemotherapy Induced Peripheral Neuropathy Current Treatment and Medical Practices

10. Chemotherapy Induced Peripheral Neuropathy Unmet Needs

11. Chemotherapy Induced Peripheral Neuropathy Emerging Therapies

12. Chemotherapy Induced Peripheral Neuropathy Market Outlook

13. Country-Wise Chemotherapy Induced Peripheral Neuropathy Market Analysis (2019–2032)

14. Chemotherapy Induced Peripheral Neuropathy Market Access and Reimbursement of Therapies

15. Chemotherapy Induced Peripheral Neuropathy Market Drivers

16. Chemotherapy Induced Peripheral Neuropathy Market Barriers

17.  Chemotherapy Induced Peripheral Neuropathy Appendix

18. Chemotherapy Induced Peripheral Neuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/